Acrivon Buys Aqilion's Phase 2-Ready Oral JAK1 Inhibitor ACR-525, Adds Immunology Pillar
ACRV sits 26% above its 52-week low of $1.27.
Summary
Acrivon acquired Aqilion's Phase 2-ready oral JAK1 inhibitor ACR-525 and a preclinical PKCθ program for undisclosed cash, with no milestones or royalties, establishing immunology and inflammation as a second strategic pillar alongside oncology.
Key Events · M&A and Partnerships · ACRV
-
Acrivon Acquires ACR-525 and PKCθ Program
An asset purchase agreement with Sweden's Aqilion AB adds a Phase 2-ready oral JAK1 inhibitor (ACR-525, formerly AQ280) and a PKCθ inhibitor preclinical program, establishing immunology and inflammation as a strategic pillar alongside oncology.
-
Cash-Only Deal, No Milestones or Royalties
Consideration was cash and undisclosed; Acrivon states it has no obligation to make additional payments, including milestone or royalty payments. Concurrently, Acrivon, Aqilion and LEO Pharma terminated all future royalty and milestone obligations on ACR-525 previously agreed between Aqilion and LEO Pharma.
-
EoE Targeted as First Indication
Eosinophilic esophagitis is the first planned indication, using one of two oral formulations designed for patients with difficulty swallowing, supported by two completed Phase 1 studies and AP3 profiling against six approved JAK inhibitors and dupilumab.
-
Deal Closed at Signing
The transaction was approved by both boards and closed concurrently with the signing of the definitive agreement on November 6, 2026; a KOL webcast is scheduled for November 10, 2026 at 4:00 p.m. ET.
Analysis · ACRV · Life Sciences
Acrivon is buying its way into immunology with a Phase 2-ready oral JAK1 inhibitor and a preclinical PKCθ program, paid for entirely in cash with no milestones or royalties owed to the seller. That structure matters: it adds a second clinical-stage asset next to the ACR-368 oncology program without stacking future payment obligations on a company that reported $90.0M in cash and runway into Q4 2027 as of the August 10-Q. Because the consideration is undisclosed, the immediate read-through is strategic rather than financial — the deal only pays off if ACR-525's selectivity versus approved JAK inhibitors holds up in eosinophilic esophagitis, where Acrivon plans to start. The November 10 KOL webcast is the next scheduled disclosure point.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACRV was trading at $1.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.3M. The 52-week trading range was $1.27 to $3.56. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.